Galectin Therapeutics Inc (NASDAQ:GALT) will post its quarterly earnings results before the market opens on Monday, August 14th. Analysts expect Galectin Therapeutics to post earnings of ($0.13) per share for the quarter.

Galectin Therapeutics (NASDAQ:GALT) last issued its quarterly earnings data on Monday, May 15th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.01. On average, analysts expect Galectin Therapeutics to post $-0.5 EPS for the current fiscal year and $-0.56 EPS for the next fiscal year.

Galectin Therapeutics Inc (NASDAQ:GALT) opened at 2.11 on Monday. The firm’s 50-day moving average price is $2.33 and its 200 day moving average price is $2.18. The firm’s market cap is $73.15 million. Galectin Therapeutics Inc has a one year low of $0.49 and a one year high of $3.68.

Several equities research analysts have commented on the company. Zacks Investment Research cut Galectin Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 26th. ValuEngine cut Galectin Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company. Galectin Therapeutics presently has an average rating of “Hold” and a consensus price target of $2.25.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.

Earnings History for Galectin Therapeutics (NASDAQ:GALT)

Receive News & Ratings for Galectin Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc and related companies with's FREE daily email newsletter.